摘要 |
The present invention relates to the treatment of Senile Dementia of the Alzheimer's Type (SDAT), or the risk thereof in a subject. More specifically, the present invention relates to the treatment of SDAT with ethanolamine phospholipids including one or more of: 1-alkyl, 2-acyl-G3P; 1-alkyl, 2-acyl-glycerol; 1-alkyl, 2-acyl-GPE; 1-alkyl, diacyl glycerol wherein sn-1 is 16:0, sn-2 is DHA, sn-3 is DHA, the sn-1 position has an alkyl ether bond, and the sn-2 and sn-3 positions have acyl bonds; 1-alkyl diacyl glycerol wherein sn-1 is 16:0, sn-2 is 18:1, sn-3 is 18:1, the sn-1 position has an alkyl ether bond, and the sn-2 and sn-3 positions have acyl bonds; triacyl glycerol wherein sn-1 is 16:0, sn-2 is DHA, sn-3 is DHA, and the sn-1, sn-2 and sn-3 positions have acyl bonds; triacyl glycerol wherein sn-1 is 16:0, sn-2 is 18:1, sn-3 is 18:1 and the sn-1, sn-2 and sn-3 positions have acyl bonds; as well as pharmaceutically acceptable salts thereof. In particular embodiments, the ethanolamine phospholipid is a 1-alkyl, 2-acyl-glycerol of the following formula: (see formula 5a) |